Rare but Serious Side Effects Though most side effects are mild, there are a few rare but serious risks that need to be considered
Semaglutide is a GLP-1 mono-agonist and tirzepatide is a GLP-1/GIP dual agonist
Many patients enhance their results with NAD+ therapy, Bioprotein+, metabolism boosters, and body contouring treatments like CoolSculpting
Advanced, pediatrician-developed nutrition from toddlerhood to adulthood
In summary, although several treatment options, including corticosteroids, minoxidil, topical immunotherapy, and Janus kinase inhibitors, are available for the management of Alopecia Areata (AA), a definitive cure for the condition has yet to be identified
Health Canada continues to identify products marketed as "For Research Use Only Not for Human Consumption." This type of labelling does not make these products legal or exempt from regulatory requirements